A 28-year-old asymptomatic pregnant woman at 12 weeks gestation presents for prenatal care. She has no personal or family history of diabetes. Her BMI is 32 kg/m². She had a random glucose of 118 mg/dL at her first visit. She asks about gestational diabetes screening. Considering her risk factors and current pregnancy, what is the most appropriate screening approach?
Q2
A 66-year-old man underwent screening colonoscopy which revealed a 1.2 cm tubular adenoma with low-grade dysplasia in the sigmoid colon that was completely removed. He has no family history of colorectal cancer. His colonoscopy 8 years ago was normal. He asks about surveillance recommendations. Considering current guidelines and competing risks, what is the most appropriate surveillance interval?
Q3
A 32-year-old woman presents for preconception counseling. She is healthy with no medical problems. Her mother and maternal aunt both had breast cancer diagnosed at ages 38 and 42, respectively. Her maternal grandmother died of ovarian cancer at age 52. The patient tested negative for BRCA1 and BRCA2 mutations 2 years ago through a commercial genetic testing panel. She asks about breast cancer screening recommendations. What is the most appropriate evaluation and management?
Q4
A 45-year-old woman presents requesting colorectal cancer screening after her sister was recently diagnosed with colon cancer at age 48. Further history reveals her sister's cancer was found to have microsatellite instability-high (MSI-H) features. The patient has no personal history of polyps or cancer and no gastrointestinal symptoms. Her sister is undergoing genetic testing for Lynch syndrome. What is the most appropriate next step in screening for this patient?
Q5
A 72-year-old woman with well-controlled hypertension and hyperlipidemia presents for follow-up. She has been getting annual mammograms since age 40. Her most recent mammogram 10 months ago was normal. She has no family history of breast cancer and has never had an abnormal mammogram. She asks if she should continue screening. Her life expectancy is estimated at 12 years based on comorbidity indices. What is the most appropriate recommendation?
Q6
A 62-year-old man with type 2 diabetes presents with a positive fecal immunochemical test (FIT) during routine screening. He has no gastrointestinal symptoms, family history of colorectal cancer, or prior colonoscopy. His hemoglobin is 13.2 g/dL. He had a screening colonoscopy 4 years ago that showed only small hyperplastic polyps. He asks if he needs another colonoscopy. What is the best approach?
Q7
A 25-year-old sexually active woman presents for her annual examination. She has had 2 lifetime sexual partners and is currently in a monogamous relationship. Her last Pap smear was at age 21 and was normal. She has no history of abnormal Pap smears or STIs. What is the most appropriate cervical cancer screening recommendation?
Q8
A 58-year-old African American man presents for a health maintenance visit. His father was diagnosed with prostate cancer at age 72. The patient asks about prostate cancer screening. His physical examination and review of systems are unremarkable. What is the most appropriate approach to prostate cancer screening for this patient?
Q9
A 68-year-old man with a 45 pack-year smoking history presents for a routine visit. He quit smoking 8 years ago. He has hypertension controlled with medication and no other comorbidities. He asks about lung cancer screening. What is the most appropriate screening recommendation for this patient?
Q10
A 52-year-old woman with no significant medical history presents for a routine health maintenance visit. She has no family history of cancer and is a nonsmoker. She asks about when she should start mammography screening. According to current USPSTF guidelines, what is the most appropriate recommendation for this patient?
Screening guidelines US Medical PG Practice Questions and MCQs
Question 1: A 28-year-old asymptomatic pregnant woman at 12 weeks gestation presents for prenatal care. She has no personal or family history of diabetes. Her BMI is 32 kg/m². She had a random glucose of 118 mg/dL at her first visit. She asks about gestational diabetes screening. Considering her risk factors and current pregnancy, what is the most appropriate screening approach?
A. Perform 3-hour oral glucose tolerance test at 16 weeks
B. Diagnose gestational diabetes based on random glucose and begin treatment
C. Perform 1-hour glucose challenge test now
D. Perform fasting glucose and hemoglobin A1c now to assess for preexisting diabetes (Correct Answer)
E. Defer screening until 24-28 weeks gestation per routine protocol
Explanation: ***Perform fasting glucose and hemoglobin A1c now to assess for preexisting diabetes***
- A **BMI ≥ 30 kg/m²** is a major risk factor necessitating early screening at the first prenatal visit to identify **pre-existing (overture) diabetes**.
- Identifying hyperglycemia early in pregnancy allows for immediate management to reduce the risk of **congenital anomalies** associated with pre-gestational diabetes.
*Perform 1-hour glucose challenge test now*
- While the **1-hour GCT** is a valid tool for early screening, standard biomarkers like **fasting plasma glucose** or **HbA1c** are also appropriate for detecting overt diabetes at the initial visit.
- The goal in the first trimester for high-risk patients is often to rule out **Type 2 Diabetes mellitus** that existed prior to pregnancy.
*Defer screening until 24-28 weeks gestation per routine protocol*
- Routine screening at **24-28 weeks** is reserved for women without significant risk factors; this patient's **obesity** mandates earlier evaluation.
- Delayed screening in obese patients may miss a window for intensive **glycemic control** during critical fetal organogenesis.
*Diagnose gestational diabetes based on random glucose and begin treatment*
- A **random glucose of 118 mg/dL** is within the normal range and is not diagnostic of either GDM (which requires >200 mg/dL with symptoms) or overt diabetes.
- Diagnosis requires structured testing such as an **HbA1c ≥ 6.5%**, fasting glucose ≥ 126 mg/dL, or a formal **oral glucose tolerance test (OGTT)**.
*Perform 3-hour oral glucose tolerance test at 16 weeks*
- The **3-hour OGTT** is typically the second step of a two-step screening process and is not indicated as an initial screening tool at 16 weeks.
- High-risk patients should be screened as soon as possible, often at the **first prenatal visit** (12 weeks in this case), rather than waiting until the second trimester.
Question 2: A 66-year-old man underwent screening colonoscopy which revealed a 1.2 cm tubular adenoma with low-grade dysplasia in the sigmoid colon that was completely removed. He has no family history of colorectal cancer. His colonoscopy 8 years ago was normal. He asks about surveillance recommendations. Considering current guidelines and competing risks, what is the most appropriate surveillance interval?
A. Annual fecal immunochemical testing
B. Repeat colonoscopy in 3 years
C. Repeat colonoscopy in 10 years
D. Repeat colonoscopy in 1 year
E. Repeat colonoscopy in 5-10 years (Correct Answer)
Explanation: ***Repeat colonoscopy in 5-10 years***
- According to the **USMSTF 2020 guidelines**, patients with **1 to 2 small (<10 mm) tubular adenomas** should have a surveillance colonoscopy in **7-10 years**; however, for a single adenoma **≥ 10 mm** (like this 1.2 cm lesion) with low-grade dysplasia, the recommended interval is **5-10 years**.
- This recommendation balances the slightly higher risk of a **larger lesion** against the **low-grade pathology** and the patient's age and overall risk profile.
*Repeat colonoscopy in 10 years*
- A strictly **10-year interval** is reserved for patients with a **normal colonoscopy** or those with only **distal hyperplastic polyps**.
- While 10 years is the upper limit of the recommended range, the presence of a **1.2 cm adenoma** requires a surveillance designation rather than a standard screening interval.
*Repeat colonoscopy in 3 years*
- The **3-year interval** is indicated for **high-risk findings** such as **≥3 adenomas**, adenomas with **villous histology**, or those with **high-grade dysplasia**.
- This patient only had a single lesion with **low-grade dysplasia**, making 3-year surveillance an over-utilization of resources.
*Repeat colonoscopy in 1 year*
- A **1-year interval** is generally only indicated for cases of **incomplete resection**, piece-meal removal of large sessile polyps, or **inadequate bowel preparation**.
- It is not appropriate for a **completely removed** 1.2 cm tubular adenoma.
*Annual fecal immunochemical testing*
- **Fecal immunochemical testing (FIT)** is a primary **screening modality**, not a surveillance tool for patients who have already been diagnosed with adenomas via colonoscopy.
- Once an adenoma is identified, the patient enters a **colonoscopy-based surveillance** program to directly monitor for recurrent or advancing lesions.
Question 3: A 32-year-old woman presents for preconception counseling. She is healthy with no medical problems. Her mother and maternal aunt both had breast cancer diagnosed at ages 38 and 42, respectively. Her maternal grandmother died of ovarian cancer at age 52. The patient tested negative for BRCA1 and BRCA2 mutations 2 years ago through a commercial genetic testing panel. She asks about breast cancer screening recommendations. What is the most appropriate evaluation and management?
A. Begin mammography at age 35 and annually thereafter
B. Recommend clinical breast exam every 6 months only
C. Begin annual mammography now
D. Refer for genetic counseling and consider expanded testing with breast MRI screening (Correct Answer)
E. Reassure that negative BRCA testing indicates average risk
Explanation: ***Refer for genetic counseling and consider expanded testing with breast MRI screening***
- Despite a negative **BRCA1/2** result, the patient's pedigree shows a **high-risk family history** (early-onset breast and ovarian cancer), which may indicate other **high-penetrance mutations** like **PALB2, TP53, or PTEN**.
- Women with a **lifetime risk >20%** based on models (e.g., **Tyrer-Cuzick**) or those with hereditary risk require **supplemental screening with Breast MRI** in addition to mammography.
*Begin annual mammography now*
- **Annual mammography alone** is insufficient for patients with a significant hereditary risk profile; **Breast MRI** is required to improve sensitivity in high-risk populations.
- Screening usually begins at age 30 or **10 years earlier** than the youngest diagnosis in the family, but current guidelines prioritize comprehensive **risk assessment** first.
*Reassure that negative BRCA testing indicates average risk*
- A negative test in the patient (without a known familial mutation) is **uninformative**; it does not rule out other genetic drivers or a strong **polygenic risk**.
- Reassuring her as "average risk" ignores the significant **familial clustering** of cancer, potentially delaying lifesaving early detection measures.
*Recommend clinical breast exam every 6 months only*
- **Clinical breast exams** lack the sensitivity to serve as a standalone management strategy for women with high **familial risk**.
- Evidence suggests that clinical exams do not significantly reduce **mortality** compared to advanced imaging protocols in hereditary cancer syndromes.
*Begin mammography at age 35 and annually thereafter*
- This delay is inappropriate; for high-risk families, screening often starts at **age 25 to 30** depending on the specific history and risk models.
- Starting at age 35 without incorporating **MRI screening** or updated **multi-gene panel testing** fails to address her specific hereditary risk profile.
Question 4: A 45-year-old woman presents requesting colorectal cancer screening after her sister was recently diagnosed with colon cancer at age 48. Further history reveals her sister's cancer was found to have microsatellite instability-high (MSI-H) features. The patient has no personal history of polyps or cancer and no gastrointestinal symptoms. Her sister is undergoing genetic testing for Lynch syndrome. What is the most appropriate next step in screening for this patient?
A. Begin colonoscopy screening at age 50 per routine guidelines
B. Defer screening until sister's genetic testing results are available
C. Begin colonoscopy screening now and repeat in 10 years if normal
D. Refer for genetic counseling and consider colonoscopy (Correct Answer)
E. Begin annual FIT testing
Explanation: ***Refer for genetic counseling and consider colonoscopy***
- The sister's diagnosis at age 48 and **MSI-H** status strongly suggest **Lynch syndrome** (Hereditary Nonpolyposis Colorectal Cancer), necessitating specialized **genetic counseling** to evaluate family risk.
- While awaiting genetic results, guidelines for a **first-degree relative** diagnosed before age 60 require **colonoscopy** starting at age 40 or 10 years earlier than the relative's diagnosis (here, age 38).
*Begin colonoscopy screening now and repeat in 10 years if normal*
- For a patient with a **first-degree relative** diagnosed before age 60, the screening interval must be every **5 years**, not 10 years.
- A **10-year interval** is only appropriate for average-risk individuals or those with a single second-degree relative with cancer.
*Begin annual FIT testing*
- **Stool-based tests** like FIT or guaiac-based FOBT are not recommended as the primary screening modality for high-risk individuals with significant **family history**.
- **Colonoscopy** is the gold standard for these patients as it allows for the detection and removal of lesions in the **proximal colon**, which is often involved in Lynch syndrome.
*Defer screening until sister's genetic testing results are available*
- Screening should not be delayed while awaiting genetic testing; since the patient is already 45 and her sister was diagnosed at 48, she is already **past the recommended start date** (age 38).
- Immediate action is required based on the known **family history** regardless of whether a specific mutation is identified.
*Begin colonoscopy screening at age 50 per routine guidelines*
- Routine guidelines for **average-risk** individuals have been lowered to age 45, but this patient is **high-risk** due to her sister's early-onset cancer.
- Waiting until age 50 ignores the **10-year rule** (screening 10 years prior to a relative's diagnosis), which would have mandated screening to begin at age 38 for this patient.
Question 5: A 72-year-old woman with well-controlled hypertension and hyperlipidemia presents for follow-up. She has been getting annual mammograms since age 40. Her most recent mammogram 10 months ago was normal. She has no family history of breast cancer and has never had an abnormal mammogram. She asks if she should continue screening. Her life expectancy is estimated at 12 years based on comorbidity indices. What is the most appropriate recommendation?
A. Perform breast MRI instead of mammography
B. Discontinue mammography screening
C. Continue annual mammography indefinitely
D. Continue mammography with shared decision-making about life expectancy (Correct Answer)
E. Switch to biennial mammography
Explanation: ***Continue mammography with shared decision-making about life expectancy***
- Major guidelines recommend continuing screening mammography as long as the patient is in good health and has a **life expectancy of at least 10 years**.
- Since her life expectancy is **12 years**, the decision to continue should involve **shared decision-making**, weighing the benefits of early detection against the potential for overdiagnosis and treatment-related harms.
*Continue annual mammography indefinitely*
- Screening should not be continued **indefinitely**; it becomes less beneficial when **life expectancy falls below 10 years** due to competing causes of mortality.
- Age alone is not the deciding factor, but the focus shifts toward **functional status and comorbidities** rather than chronological age.
*Switch to biennial mammography*
- While some organizations (like the USPSTF) support **screening every two years** for older women, the primary consideration for discontinuing or continuing is the **10-year life expectancy threshold**.
- Switching frequency does not address the core clinical question of whether the patient still benefits from screening based on her **prognostic outlook**.
*Discontinue mammography screening*
- Breast cancer screening should generally be discontinued only when **life expectancy is less than 10 years**, which is not the case for this patient.
- Given her **well-controlled hypertension** and good health status, she is still likely to benefit from the detection of **early-stage malignancies**.
*Perform breast MRI instead of mammography*
- **Breast MRI** is not used for routine screening in average-risk women and is generally reserved for those with a **high lifetime risk (>20%)** or specific genetic mutations.
- This patient has **no family history** and no high-risk features that would justify the use of MRI over **standard screening mammography**.
Question 6: A 62-year-old man with type 2 diabetes presents with a positive fecal immunochemical test (FIT) during routine screening. He has no gastrointestinal symptoms, family history of colorectal cancer, or prior colonoscopy. His hemoglobin is 13.2 g/dL. He had a screening colonoscopy 4 years ago that showed only small hyperplastic polyps. He asks if he needs another colonoscopy. What is the best approach?
A. Check iron studies and repeat FIT annually
B. Order CT colonography instead
C. Repeat FIT in 6 months
D. Reassure and continue routine screening in 6 years
E. Proceed with diagnostic colonoscopy (Correct Answer)
Explanation: ***Proceed with diagnostic colonoscopy***
- A **positive fecal immunochemical test (FIT)** is a high-risk finding that requires timely evaluation with **colonoscopy** to identify **colorectal cancer** or advanced adenomas.
- Even with a **negative colonoscopy** four years ago, a new positive FIT takes precedence as it indicates active **occult bleeding**, necessitating a repeat examination.
*Repeat FIT in 6 months*
- Guidelines state that once a FIT is positive, the next step is **diagnostic colonoscopy**, not repeating the screening test.
- Repeating the FIT could lead to a **false negative result** due to the intermittent nature of tumor bleeding, causing a dangerous delay in diagnosis.
*Order CT colonography instead*
- **CT colonography** is generally reserved for patients who cannot tolerate a standard colonoscopy or have had an incomplete procedure.
- If an abnormality is found on CT, the patient would still require a **follow-up colonoscopy** for biopsy or resection, making it a less efficient diagnostic path.
*Reassure and continue routine screening in 6 years*
- While a 10-year interval is standard for **average-risk patients** with a normal colonoscopy, it no longer applies once a patient has a **positive screening biomarker**.
- Small **hyperplastic polyps** found 4 years ago are considered low-risk, but they do not negate the significance of a new positive FIT which may indicate an **interval cancer**.
*Check iron studies and repeat FIT annually*
- The absence of **iron-deficiency anemia** (hemoglobin 13.2 g/dL) does not rule out the presence of **adenocarcinomas** or large polyps.
- FIT is intended as a screening tool; once positive, the patient enters a **diagnostic pathway** where annual FIT screening is no longer appropriate until the colon is cleared.
Question 7: A 25-year-old sexually active woman presents for her annual examination. She has had 2 lifetime sexual partners and is currently in a monogamous relationship. Her last Pap smear was at age 21 and was normal. She has no history of abnormal Pap smears or STIs. What is the most appropriate cervical cancer screening recommendation?
A. No screening needed until age 30
B. Pap smear plus HPV co-testing every 5 years
C. Pap smear annually
D. HPV testing alone every 5 years
E. Pap smear every 3 years (Correct Answer)
Explanation: ***Pap smear every 3 years***
- For women aged **21 to 29**, the current screening guideline is **cytology alone** (Pap smear) every **3 years** regardless of sexual history.
- **HPV co-testing** or primary HPV testing is generally discouraged in this age group due to the high prevalence of **transient HPV infections** that resolve without clinical significance.
*Pap smear annually*
- **Annual Pap smears** are no longer recommended for the general population as they increase the risk of unnecessary interventions and do not significantly improve **cancer detection** over longer intervals.
- Screening intervals were extended to reduce the diagnosis and treatment of **low-grade lesions** that would otherwise regress on their own.
*Pap smear plus HPV co-testing every 5 years*
- **Co-testing** is a preferred strategy only for women aged **30 to 65** because persistent HPV infection is more likely to indicate clinical disease in older cohorts.
- Using this method in a 25-year-old leads to excessive **colposcopies** for infections that the immune system would likely clear naturally.
*HPV testing alone every 5 years*
- While **primary HPV testing** every 5 years is an option for women starting at age 25 or 30 according to some guidelines, medical boards typically follow the **USPSTF/ACOG** recommendation for **cytology alone** under age 30.
- In the 21–29 age range, **cytology** remains the most established and widely tested screening standard in board exams.
*No screening needed until age 30*
- Cervical cancer screening must begin at **age 21**, regardless of the age of sexual debut or the presence of risk factors.
- Delaying screening until **age 30** would miss the opportunity for early detection of **cervical intraepithelial neoplasia (CIN)**.
Question 8: A 58-year-old African American man presents for a health maintenance visit. His father was diagnosed with prostate cancer at age 72. The patient asks about prostate cancer screening. His physical examination and review of systems are unremarkable. What is the most appropriate approach to prostate cancer screening for this patient?
A. Recommend against PSA screening due to current guidelines
B. Defer PSA screening until age 60
C. Perform PSA only if digital rectal exam is abnormal
D. Begin PSA screening immediately without discussion
E. Engage in shared decision-making about PSA screening (Correct Answer)
Explanation: ***Engage in shared decision-making about PSA screening***
- For men at higher risk, such as **African Americans** or those with a **family history**, the **USPSTF guidelines** emphasize **shared decision-making** starting between ages 45-55.
- Screening with **Prostate-Specific Antigen (PSA)** should only occur after a thorough discussion regarding the potential for **overdiagnosis** and the morbidity of follow-up procedures.
*Begin PSA screening immediately without discussion*
- Screening should never be initiated without a **shared decision-making** process, as the benefits of screening are marginal relative to the risks of **overtreatment**.
- Bypassing the discussion ignores the **Grade C recommendation** which mandates clinical judgment and patient values in the decision.
*Defer PSA screening until age 60*
- Waiting until age 60 is inappropriate for high-risk patients, as **African American** men often develop more aggressive forms of prostate cancer at an earlier age.
- Guidelines generally suggest starting the screening discussion for high-risk individuals between **ages 45 and 50**.
*Recommend against PSA screening due to current guidelines*
- Current guidelines provide a **Grade C recommendation** for men aged 55-69, meaning screening is not discouraged but must be individualized.
- This patient's **African American ethnicity** is a significant risk factor that makes periodic screening a more viable consideration than for the general population.
*Perform PSA only if digital rectal exam is abnormal*
- The **Digital Rectal Exam (DRE)** has poor **sensitivity and specificity** and is no longer recommended as a primary or gatekeeping screening tool.
- Most prostate cancers are identified through **PSA elevation** rather than abnormalities detected on a manual exam.
Question 9: A 68-year-old man with a 45 pack-year smoking history presents for a routine visit. He quit smoking 8 years ago. He has hypertension controlled with medication and no other comorbidities. He asks about lung cancer screening. What is the most appropriate screening recommendation for this patient?
A. Low-dose CT scan every 2 years
B. Annual chest X-ray
C. PET-CT scan annually
D. Annual low-dose CT scan (Correct Answer)
E. No screening indicated due to smoking cessation
Explanation: ***Annual low-dose CT scan***
- The **USPSTF** recommends annual screening with **low-dose computed tomography (LDCT)** for adults aged **50 to 80 years** who have at least a **20 pack-year** smoking history.
- Screening is indicated for those who currently smoke or have **quit within the past 15 years**; this patient qualify as he quit only 8 years ago.
*Annual chest X-ray*
- **Chest X-rays** lack the sensitivity to detect small, early-stage nodules and have not been shown to reduce **lung cancer mortality**.
- Large trials, such as the **NLST**, demonstrated that LDCT is superior to radiography for identifying resectable malignancies.
*No screening indicated due to smoking cessation*
- Screening should only be discontinued if the patient has not smoked for **15 years** or more, or if they develop a life-limiting condition.
- Since this patient only quit **8 years ago**, he remains at an elevated risk that warrants ongoing surveillance.
*Low-dose CT scan every 2 years*
- The established protocol for lung cancer screening is **annual** (every year), not biennial, to ensure timely detection of rapidly growing tumors.
- Changing the frequency to every 2 years significantly decreases the **sensitivity** of a screening program for early intervention.
*PET-CT scan annually*
- **PET-CT scans** are not used for screening due to high costs, significant **radiation exposure**, and a high rate of false positives.
- PET-CT is reserved for the **staging** of confirmed malignancy or characterizing suspicious nodules found on an initial LDCT.
Question 10: A 52-year-old woman with no significant medical history presents for a routine health maintenance visit. She has no family history of cancer and is a nonsmoker. She asks about when she should start mammography screening. According to current USPSTF guidelines, what is the most appropriate recommendation for this patient?
A. Begin annual mammography at age 45 years
B. Defer mammography until age 55 years
C. Begin biennial mammography at age 50-74 years with shared decision-making (Correct Answer)
D. Begin mammography only if she develops symptoms
E. Begin annual mammography immediately
Explanation: ***Begin biennial mammography at age 50-74 years with shared decision-making***
- Per the **USPSTF guidelines**, women aged **50 to 74 years** are recommended to undergo **biennial screening mammography** to reduce breast cancer mortality.
- While recent updates have shifted towards starting at age 40, the standard **Grade B recommendation** emphasizes the strongest evidence for the **50-74 age bracket** in average-risk patients.
*Begin annual mammography immediately*
- The **USPSTF** generally recommends **biennial (every two years)** screening rather than **annual mammography** to balance benefits against the risks of overdiagnosis.
- Immediate annual screening in an average-risk 52-year-old exceeds the frequency suggested by the **USPSTF framework** for routine maintenance.
*Begin annual mammography at age 45 years*
- **Annual screening at age 45** is a recommendation often associated with the **American Cancer Society (ACS)**, not the **USPSTF**.
- The **USPSTF** focuses on **biennial intervals** which have been shown to provide a similar mortality benefit with significantly fewer **false positives**.
*Defer mammography until age 55 years*
- Deferring until **age 55** would miss the peak benefit window for screening in a woman who is already 52 years old.
- Both **ACS** and **USPSTF** guidelines agree that screening should have commenced by **age 50** at the latest for average-risk individuals.
*Begin mammography only if she develops symptoms*
- **Mammography** is a **screening tool** intended to detect cancer in **asymptomatic women** before a palpable mass or symptoms develop.
- Waiting for symptoms would negate the purpose of screening, often resulting in detection at a **more advanced stage** with a poorer prognosis.
